Cite
1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
MLA
F.S. Hodi, et al. “1082MO 5-Year Characterization of Complete Responses in Patients with Advanced Melanoma Who Received Nivolumab plus Ipilimumab (NIVO+IPI) or NIVO Alone.” Annals of Oncology, vol. 31, Sept. 2020, pp. S734–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........49fbd141fb460af07a1bd872c8943853&authtype=sso&custid=ns315887.
APA
F.S. Hodi, Kenneth F. Grossmann, Céleste Lebbé, Jason Chesney, John Wagstaff, Sandra Re, J.M.G. Larkin, Jessica C. Hassel, Anna C. Pavlick, Georgina V. Long, P.A. Ascierto, C. Robert, Ivan Marquez-Rodas, Jedd D. Wolchok, Marcus O. Butler, W. van Dijck, Michael A. Postow, Oliver Bechter, Dirk Schadendorf, & J.-J. Grob. (2020). 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. Annals of Oncology, 31, S734–S735.
Chicago
F.S. Hodi, Kenneth F. Grossmann, Céleste Lebbé, Jason Chesney, John Wagstaff, Sandra Re, J.M.G. Larkin, et al. 2020. “1082MO 5-Year Characterization of Complete Responses in Patients with Advanced Melanoma Who Received Nivolumab plus Ipilimumab (NIVO+IPI) or NIVO Alone.” Annals of Oncology 31 (September): S734–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........49fbd141fb460af07a1bd872c8943853&authtype=sso&custid=ns315887.